]> 2026-04-12T02:25:44-07:00 VAL-083 (Dianhydrogalactitol) 0 en The most common adverse event reported is myelosuppression, including instances of neutropenia and lymphopenia. A few patients experienced serious adverse events possibly related to VAL-083, indicating a moderate toxicity profile. Ongoing monitoring and management of these side effects are essential to minimize risks to patients. 2025-01-18T08:26:04Z 2460693.8514352 VAL-083 (Dianhydrogalactitol) 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","VAL-083 represents an innovative approach to treating recurrent GBM, leveraging a unique mechanism of action that differs from other alkylating agents. Its effectiveness in patients with specific genetic markers, such as an unmethylated MGMT promoter, underscores the importance of targeted genetic testing in guiding GBM treatment. Further studies are crucial to confirm these preliminary findings and fully establish VAL-083's therapeutic potential and safety profile in GBM treatment."] VAL-083 (Dianhydrogalactitol)# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name